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Abstract The development of novel affinity probes for can-
cer biomarkers may enable powerful improvements in analyt-
ical methods for detecting and treating cancer. In this report,
we describe our use of capillary electrophoresis (CE) as the
separation mechanism in the process of selecting DNA
aptamers with affinity for the ovarian cancer biomarker
HE4. Rather than the conventional use of cloning and se-
quencing as the last step in the aptamer selection process,
we used high-throughput sequencing on an Illumina platform.
This data-rich approach, combinedwith a bioinformatics pipe-
line based on freely available computational tools, enabled the
entirety of the selection process—and not only its endpoint—
to be characterized. Affinity probe CE and fluorescence an-
isotropy assays demonstrate the binding affinity of a set of
aptamer candidates identified through this bioinformatics
approach.
Keywords Aptamer . CE-SELEX . HE4 . Ovarian cancer .
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Introduction
The long-term survival of ovarian cancer patients correlates
strongly with stage at diagnosis. Local disease, confined to
one or both ovaries, responds well to existing treatments, with
5-year survival rates averaging 92 % [1]. By contrast, the 5-
year survival rate for patients with metastatic cancer at distant
sites is 27 %. These data—and the fact that most ovarian
cancers are not diagnosed until metastasis has occurred—pro-
vide compelling motivation for the discovery and validation
of new ovarian cancer biomarkers that may enable earlier
detection.
Using comparative hybridization assays on an array of 21,
500 ovarian cDNAs, Hood and coworkers identified the HE4
(WFDC2) gene as more highly expressed in ovarian cancer
tissue than in noncancerous ovarian epithelium [2]. This ob-
servation was supported by serial analysis of gene expression,
which also foundHE4 to be amplified in ovarian cancer [3]. A
2003 study demonstrated that serum HE4 protein is detectable
via double-determinant immunoassay and is an ovarian cancer
biomarker with sensitivity and specificity comparable to that
of CA125, the clinical Bgold standard,^ but with the likely
advantage of lower false-positive rates in patients with benign
disease [4]. Thorough characterization of protein expression
in various tissue types via immunostaining confirmed that
normal ovarian epithelium does not express HE4, whereas
the protein is strongly expressed on serous and endometrioid
tumors, which together constitute the vast majority of ovarian
cancer cases [5, 6]. In 2008, the FDA approved the use of a
serum HE4 assay for monitoring recurrence in patients with
epithelial ovarian cancer. The combination of HE4 and
CA125, when used in the Risk of Ovarian Malignancy Algo-
rithm (ROMA) test, is effective at classifying women present-
ing with a pelvic mass into high- or low-risk categories, which
enables the triage of women likely to have ovarian cancer to
clinical settings and surgeons with appropriate expertise [7, 8].
The FDA approved this use of ROMA in 2011. Most relevant
to the challenge of early detection are the results of ELISA
assays performed on banked serum samples collected 1 to
18 years prior to ovarian cancer diagnosis [9]. That study
Published in the topical collection Capillary Electrophoresis of
Biomolecules with guest editor Lisa Holland.
* Rebecca J. Whelan
rwhelan@oberlin.edu
1 Department of Chemistry and Biochemistry, Oberlin College, 119
Woodland Street, Oberlin, OH 44074, USA
Anal Bioanal Chem (2015) 407:6965–6973
DOI 10.1007/s00216-015-8665-7
showed the mean concentrations of HE4 (along with serum
markers CA125 and mesothelin) in serum samples from can-
cer patients began to visually increase 3 years before diagno-
sis, reaching detectable levels 1 year before clinical presenta-
tion [9]. Novel analytical approaches to HE4 detection may
therefore contribute to early detection of ovarian cancer and
associated improvement in patient outcomes.
To complement existing antibody-based detection strate-
gies, many investigators have explored the use of nucleic acid
aptamers [10, 11] as affinity probes. Aptamers share with an-
tibodies the property of high-affinity and high-selectivity
binding to a target of interest, while having distinct benefits
over antibodies in their greater ease of labeling and facile
regeneration of native confirmation upon heat cycling. Along
with their entirely in vitro development process—the use of
animals or cells is not required—these attributes have made
aptamers an attractive recognition element employed in a va-
riety of analytical applications [12–14]. Various modes of
aptamer selection, referred to as Systematic Evolution of Li-
gands by EXponential enrichment (SELEX), have been de-
veloped [15, 16]. Briefly, a randomized Blibrary^ of oligonu-
cleotides is subject to iterative cycles of (1) incubation with
the target, (2) separation to resolve bound oligos from un-
bound, and (3) amplification to reproduce those oligos
possessing desired binding attributes. In our development of
DNA aptamers with affinity for HE4, we used a capillary
electrophoresis (CE)-based separation mechanism [17, 18].
Owing to the high applied field strength used in CE separa-
tions, CE-SELEX enables efficient separation of bound and
unbound oligos. This selection method has been shown to
converge the unselected library onto functional aptamers in
fewer rounds than selection methods based on column chro-
matography or nitrocellulose filtration [19].
Traditionally, the final stage of the aptamer selection pro-
cess has been to clone the selected oligonucleotide pool into a
bacterial expression system, sequence these oligos by Sanger
methods, and characterize the affinity of the identified se-
quences for the target. It has been shown, however, that such
approaches can fail to identify high-affinity aptamers [20].
The recent proliferation of high-throughput sequencing
(HTS) techniques, also known as next-generation sequencing,
deep sequencing, or massively parallel sequencing [21, 22],
has made it possible to sequence pools of aptamer candidate
oligos with significantly greater coverage than a clone-and-
sequence approach. HTS enables the full evolutionary path of
the SELEX process to be characterized, not only its endpoint
[23]. As a result, better aptamers can be selected with fewer
rounds of selection [24], even in a single round [25], by re-
moving the need for the pool to fully converge on a consensus
sequence or sequences. Advantages of this approach include
reducing time and materials required and minimizing the op-
portunities for the introduction of polymerase chain reaction
artifacts [26] that can bias selection, ultimately causing the
loss of high-affinity binders [27]. Similarly, sequences identi-
fied by their fold enrichment, rather than raw read counts, can
locate high-affinity binders that traditional Sanger sequencing
can miss [20]. HTS can also reduce the number of sequences
needing to be tested in vitro, when coupled with bioinformat-
ics, by identifying clusters of oligos with a common sequence
or structure [28]. A novel method of aptamer affinity determi-
nation, MPBind [29], uses a statistical analysis of HTS data to
determine aptamer affinity and may prove valuable to users in
this field.
Here, we report on our use of CE-SELEX to identify DNA
aptamers with affinity for the ovarian cancer marker HE4.
Selected DNA was subject to HTS on the Illumina platform.
Enrichment and clustering analysis were performed in-house




Oligonucleotides—including unselected DNA library, poly-
merase chain reaction (PCR) and sequencing primers, and
labeled aptamers for in vitro testing—were purchased from
Integrated DNA Technologies (Coralville, IA). The se-
quences, previously reported by Bowser and coworkers [23]
were forward primer 5′-FAM-AGC AGC ACA GAG GTC
AGA TG-3′, reverse primer 5′-biotin-TTC ACG GTA GCA
CGC ATA GG-3′, and single-stranded DNA (ssDNA) library
5′-FAM-AGC AGC ACA GAG GTC AGA TG (N)25 CCT
ATG CGT GCT ACC GTG AA-3′. Nuclease-free water,
25 mM MgCl2, 5.0 U/μL Taq polymerase (for PCR), and
Blue/Orange 6× loading dye (for gel loading) were purchased
from Promega (Madison, WI). Deoxyribonucleotide triphos-
phates (dNTPs, 10 mM stock) were obtained from QIAGEN,
Inc. (Valencia, CA). NuSieve GTG agarose was purchased
from Cambrex BioScience (Rockland, ME). 5× Tris Borate
EDTA (TBE) was made from TRIZMA Base and boric acid
purchased from Sigma (St. Louis, MO), and 0.5 M EDTA
(OmniPur; Gibbstown, NJ). The buffer used for aptamer se-
lection and CE separation was 25 mM Tris, 192 mM glycine,
5 mM KH2PO4, pH 8.3 (TGK) prepared from Thermo Scien-
tific Tris-Glycine powder (Asheville, NC), and KH2PO4 from
Mallinckrodt Chemical Works (St. Louis, MO) using
18.2 MΩ cm water as a diluent. Streptavidin-agarose was
purchased from Thermo Scientific Pierce Biotechnology Inc.
(Rockford, IL). Bio-Rad columns were purchased from Bio-
Rad Technologies (Hercules, CA). Binding and washing
(B&W) buffer (10 mM Tris, 2 mM NaCl, 1 mM EDTA at
pH 7.6, 2× concentration) was made from NaCl purchased
from VWR (Bridgeport, NJ). Absolute ethanol was sourced
from AAPER Alcohol and Chemical Co. (Shelbyville, KY).
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Human recombinant HE4 protein with a glutathione-S-trans-
ferase purification tag (HE4-GST), GST protein, and the stor-
age buffer for both proteins (50 mM Tris-HCl containing
10 mM reduced glutathione, pH 8.0) were purchased from
Abnova (Taipei, Taiwan).
Capillary electrophoresis and aptamer selection
Capillary electrophoresis aptamer selection was performed on
a Beckman Coulter P/ACEMDQ system (Fullerton, CA) with
exchangeable UV absorbance and laser-induced fluorescence
(LIF) detectors (488 nm excitation, 520 emission). The capil-
lary was 51.3 cm in length and 42.5 cm from inlet to window,
with an inner diameter of 50 μm and an outer diameter of
360 μm (Polymicro Technologies Inc., Phoenix, AZ).
Before incubation with target protein, DNAwas heated to
95 °C for 3 min and cooled on ice. For each selection round,
DNA, target protein, and TGK buffer were combined in 10μL
total volume. The mixture was incubated at 25 °C for 30 min.
The equilibrated sample was injected (2 psi for 5 s) and sep-
arated (25 kV). LIF detection was used to monitor the separa-
tion. During a positive selection round, the eluate was collect-
ed into 48 μLTGK buffer until the unbound DNA peak began
to elute. In a negative selection round, unbound DNAwas also
collected into a separate vial containing 48 μL TGK buffer.
The injection, separation, and collection process was repeated
two more times. The capillary was rinsed with 0.15 M NaOH,
water, and TGK buffer between each run. Input DNA concen-
tration was determined by absorbance at 260 nm on a
NanoDrop 2000 UV-vis spectrophotometer. For the first
round of selection, the unselected library was used, with
[DNA]=10 μM in the incubated sample. Subsequent rounds
of selection used DNA collected, amplified, and purified from
the previous round as the input DNA. The concentration of
input DNA in later selection rounds was 50, 150, 150, 200,
300, and 300 nM, respectively (Table 1).
PCR amplification
All PCRs were done using a Mastercycler Personal from
Eppendorf AG (Hamburg, Germany). Amplification of
selected DNA involved two steps: determination of optimal
cycle number and preparative PCR. Master mix was made by
combining 484 μL nuclease-free water, 16 μL dNTPs, 20 μL
each of forward and reverse primers, 96 μL MgCl2, and
160 μL colorless 6× buffer. After mixing, 149.25 μL of the
master mix was removed and combined with 0.75 μL Taq
polymerase. To 94.5 μL of this completed master mix we
added 5.5 μL of DNA collected during selection. This mixed
solution was divided equally over thin-walled tubes that were
subject to PCR for different numbers of cycles, where each
cycle involved three steps: denaturing (95 °C, 30 s), annealing
(53 °C, 15 s), and extension (72 °C, 15 s). The samples, which
contained different amounts of amplified product, were re-
solved on a 4 % agarose gel at an applied voltage of 85 V.
Gels were imaged on a Kodak Gel Logic 200 Integrated Illu-
mination Cabinet and Imaging System, and photos were dig-
itally improved using Kodak Molecular Imaging software,
version 4.5 (Rochester, NY). The fluorescence of forward
primers and amplified product enabled visualization of DNA
without ethidium bromide staining. The number of cycles that
yielded a visible product bandwithminimal primer and no by-
products was used for preparative PCR. In preparative PCR,
646.75 μL of master mix was combined with 3.25 μL Taq
polymerase. Seventy microliters of this completed master
mix was combined with 5.5 μL of collected DNA in eight
separate vials. Completed master mix without added DNA
was run as a negative control. After completing the optimal
number of PCR cycles, 10 μL of each sample and the control
were visualized on a 4 % agarose gel to confirm yield and
purity. Remaining samples were pooled and subject to single
stranding.
Single stranding
Double-stranded PCR product was converted to single-
stranded DNA using streptavidin columns. For the single-
stranding process, 300 μL of streptavidin-agarose slurry was
placed in a Bio-Rad chromatography column and washed five
times with 500-μL portions of 2× B&W buffer. Pooled PCR
product was loaded onto the column with an equal volume of
2× B&W buffer, and the mixture was allowed to incubate at
room temperature with gentle vortexing every 5 min for
30 min. The column was then washed ten times, with the
following buffers, in order of decreasing ionic strength: four
washes with 550 μL 2× B&W buffer; five washes with
550 μL 1× B&W buffer; and one wash with 500 μL ultrapure
H2O. Thirty micromoles of NaOH (200 μL of 0.150 M
NaOH) was then added to the column, gently vortexed, and
incubated at 37 °C for 10 min to denature double-stranded
DNA (dsDNA). The column was then gently vortexed and
the unretained ssDNA (containing the FAM forward primer)
eluted into 30 μmol of acetic acid (200 μL of 0.15 M acetic
acid) to neutralize the hydroxide. The solution was buffered
Table 1 Incubation conditions used during rounds of aptamer selection
Round Pos/neg Target [Target] DNA source [DNA]
R1 Pos HE4-GST 50 nM Library 10 μM
R2+ Pos HE4-GST 10 nM R1 50 nM
R2− Neg GST 50 nM R2+ 150 nM
R3+ Pos HE4-GST 5 nM R2− 150 nM
R3− Neg GST 25 nM R3+ 200 nM
R4 Pos HE4-GST 1 nM R3− 300 nM
R5 Pos HE4-GST 0.5 nM R4 300 nM
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by the addition of 40 μL of 3 M sodium acetate, followed by
1000 μL of cold 100 % ethanol to precipitate ssDNA. The
NaOH elution process was repeated into a separate collection
tube, and the two samples (containing ssDNA in ethanol) were
incubated at −20 °C or on wet ice for at least 2 h but not more
than 12 h. The two portions of eluted DNAwere centrifuged at
13,200 RPM for 45 min at 4 °C. Supernatant was pipetted
from each tube, leaving 100 μL DNA-containing solution.
One milliliter of cold 70 % ethanol was then added to both
tubes. After 20 min of spinning at 4 °C, supernatant was re-
moved, leaving 50 μL. The cold ethanol washing process was
repeated; after centrifugation, supernatant was carefully re-
moved, leaving 25 μL. Both portions of eluted DNA were
then dried in a Speedvac at medium heat for 10 min, followed
by 5 min spinning at room temperature. Each tube was then
reconstituted in 15 μL of TGK buffer. The DNA was then
combined and divided as follows: 10 μL was archived for
sequencing, 10 μL was archived for NanoDrop and bulk af-
finity measurements, and 10 μL was used for the next round
of selection.
Sequencing and bioinformatics
After aptamer selection was complete, DNA collected from
each round was amplified using Illumina sequencing primers.
Archived DNA from each round was diluted to 100 nM using
ultrapure water. Each sample was assigned a unique reverse
primer containing the index used for barcoding. Master mix
containing all PCR reagents except Taq polymerase and the
reverse primers was made from 563 μL nuclease-free water,
18 μL dNTPs, 22 μL forward primer, 108 μL MgCl2, and
180 μL colorless buffer. To 97 μL of this mix was added
0.5 μL of Taq polymerase and 2.4 μL of the specific reverse
primer. Seventy-four microliters of this mixed solution was
added to 1 μL DNA solution; samples and controls were am-
plified by PCR using an optimized cycle number. PCR prod-
ucts were imaged on a 3 % agarose gel containing 1 μg/mL
ethidium bromide to confirm yield and the absence of contam-
inants or by-products. Samples were sequenced at the Univer-
sity of Wisconsin Biotechnology Center DNA Sequencing
Facility.
Bioinformatic screening of the sequenced DNA used a
data pipeline based on freely available software, with the
exception of enrichment analysis, which used a Python pro-
gram written in-house. This program (enrichment.py) has
been made available on GitHub at https://github.com/
rebeccawhelan/PythonEnrichment. After a preliminary
analysis of the FastQC files to ensure the sequencing was
successful, data were sent into a Biopieces pipeline. Each
round’s data was individually read into the pipeline using
read_fastqc. Selection primers were removed with
remove_primers, using a 5 % mismatch tolerance and
a 0 % tolerance for insertions and deletions. All bases
beyond the reverse sequence primer (i.e., adaptors and
sequencing primers) were removed in this step. These
sequences were then filtered using grab to select only
sequences with a length of 25±2. These data were
processed with uniq_seq, creating one record for each
sequence with associated count information. The records
were sorted by read count in descending order using
sort_records and written to a file as tabular data.
From there, the processed data were taken through
enrichment analysis, a novel program that determines the
fold enrichment for sequences across rounds of selection.
Random regions only (with primers excluded) were used
in the enrichment analysis to simplify computation; with
respect to the enrichment over selection rounds, the primer
information is redundant, being identical across all
sequences. Fold enrichment has been shown to be a more
reliable indicator of binding affinity than read counts [27].
Using CD-HIT-EST [30], the top 1000 most enriched se-
quences from each round were clustered by sequence ho-
mology to determine possible emergent motifs. Sequences
were clustered with their primers attached to a sequence
identity threshold of 0.8 and assigned to clusters by the
highest identity across all clusters.
Affinity probe capillary electrophoresis
Affinity probe capillary electrophoresis affinity assays were
performed using a Beckman P/ACE MDQ (Beckman Coul-
ter, Fullerton, CA) equipped with an argon-ion laser. An
unmodified fused silica capillary (Polymicro Technologies,
Phoenix, AZ; ID=50 μm, OD=360 μm, total length=
49.5 cm, length from inlet to detector=39.6 cm) was held
at 25 °C. Samples were injected from the outlet end, and
negative polarity was applied to minimize the distance from
injection to detection (length to detector=9.9 cm). Each
sample contained 10 nM FAM-labeled aptamer (synthesized
as a 25mer sequence without primer regions), 20 nM fluo-
rescein (internal standard), and 1 mg/mL BSA. TGK was
used both as the diluent in sample preparation and as the
electrophoresis buffer. To prepare samples, a bulk solution
of aptamer in TGK was heated to 90 °C for 3 min, and then
put on ice to cool. Fluorescein and bovine serum albumin
(BSA) were then added, and the solution was distributed
over an appropriate number of sample tubes. Finally, protein
(HE4-GST or GST, in separate experiments) was added to a
final concentration ranging from 0 to 240 nM. The volume
of protein plus protein buffer was constant in all samples.
Pressure injection (0.3 psi, 5 s) was used to introduce the
sample onto the capillary; separation was achieved by the
application (in negative polarity) of 30 kV. Run time was
3 min. The fluorescence was excited at 488 nm and detected
at 520 nm. Peak heights were determined by the instrument
control software (32 Karat). The change in the size of the
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free DNA aptamer peak, relative to the internal standard,
was used to indicate the complex formation between
aptamer and protein. Data were fit with an isotherm
equation:
Ratioed peak height ¼ constant
1þ Kd= T þ 0:5 Aþ T þ Kd− Aþ T þ Kdð Þ2−4 A T
 0:5    
where T is protein concentration (varied) and A is aptamer
concentration (constant, typically 10 nM), using IgorPro (v.
6.12) graphing software.
Fluorescence anisotropy
Fluorescence anisotropy was measured using a SpectraMax
M5 multimode plate reader with polarizing optics (Molecu-
lar Devices, Sunnyvale, CA). Tested aptamers were ordered
from Integrated DNA Technologies, Inc. (Coralville, IA)
with a 5′ TEX615 (Texas Red) fluorophore. One hundred
nanomolar DNA aptamer in buffer (TGK) was heated to
95 °C for 3 min, cooled to 4 °C, then allowed to warm to
room temperature. Heat-cycled DNA solution was combined
with HE4-GST at a range of final concentrations from 0 to
750 nM in the presence of 0.1 mg/mL bovine serum albu-
min (BSA). The volume of protein plus protein buffer was
constant across all samples. After incubating for at least
30 min in the dark at 25 °C, samples were loaded in dupli-
cate (70 μL/well) into a 96-well Fluotrac 200 black immu-
nology plate (USA Scientific, Ocala, FL) and analyzed in
the SpectraMax, with temperature held at 25 °C. The λex for
fluorescence anisotropy was 585 nm, λem was 635 nm, and
the wavelength cut-off was 610 nm. Raw data (fluorescence
emission parallel and perpendicular to the exCitation) were
blank-corrected before the anisotropy values were calculat-





T þ 0:5 Aþ T þ Kd  Aþ T þ Kdð Þ2  4 A T
 0:5    
where T is protein concentration (varied), A is aptamer con-
centration (constant), r is the anisotropy measured in the pres-
ence of protein, and r0 is the anisotropy in the absence of
protein, using IgorPro (v. 6.12) graphing software.
Results and discussion
An unselected DNA library with N=25 random region was
used as the input to the selection process because it provided a
good balance of sequence diversity, coverage, and computa-
tional tractability. Assuming that each base is equally likely to
appear at each position in the random region, there are 425
(~1×1015) possible sequences in such a library. In our selec-
tion, we used 100 pmol (~6×1013 molecules) of DNA as the
initial input, giving any individual sequence an expected
abundance of 0.05 (a library with N=23 would give an ex-
pected abundance of 1). Using a longer random region would
result in lower coverage of sequence space that could result in
the loss of useful motifs, whereas a shorter random region
might lack the complexity to form relevant secondary and
tertiary structures involved in target binding.
Table 1 shows the conditions used in our CE-SELEX pro-
cess. Each incubation condition was completed once, in the
order shown (R1 to R5). Positive selection rounds involved
incubating DNA oligonucleotides (either unselected library or
single-stranded DNA from a previous selection round) with
HE4-GST. Nonequilibrium separation conditions were ap-
plied to pre-equilibrated mixtures, as is common in
capillary-based aptamer selection. At the pH of our electro-
phoresis buffer, the protein target eluted first, followed by
protein-aptamer complexes, and finally the sequences of un-
bound DNA. We collected solution that eluted during the run
and terminated collection before unbound DNA eluted. As
received, the protein target of interest (HE4) was covalently
attached to a purification tag (GST). To avoid selecting
aptamers with affinity for GST, we included two rounds of
negative selection, in which GST was the protein target and
only the unbound DNA—comprising those oligos without
affinity for GST—was collected. DNA collected from each
selection round was then amplified by PCR to an optimal
number of cycles and single stranded to generate the ssDNA
for the next selection round. Figure 1 demonstrates the sensi-
tivity of the PCR product to the number of rounds of PCR
conducted. Insufficient rounds of PCR mean that the product
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of interest is not formed, but too many rounds of PCR result in
the consumption of the dsDNA product of interest and the
formation of by-products. The sensitivity of PCR when am-
plifying aptamers has been thoroughly described by Krylov’s
group [26]; we include a cycle-determining step in each
SELEX round and amplify selected DNA to the optimal cycle
number to avoid this problem. In the cycle-determining step,
identically prepared samples were subject to different num-
bers of PCR cycles. These samples were resolved in parallel
lanes on an unstained agarose gel and imaged on a UV illu-
minator through the excitation of the fluorescein primer. The
optimal cycle number was that number of PCR cycles that
gave a clearly visible band of the desired dsDNA product,
but for which no by-products were visible on the gel.
The bioinformatics pipeline used after the completion of
the CE-SELEX process is illustrated in Fig. 2. DNA archived
after each selection round was sequenced on an Illumina plat-
form. Information about the resulting sequence data is shown
in Table 2. The number of oligo sequences yielded by this
next-generation sequencing technique is significantly larger
(max=10.1×106; min=2.7×106; average=6.4×106) than
what would typically be achievable with a clone-and-
sequence approach. Sequence duplication, reported as a
percent, is the number of duplicate sequences relative to
unique. Two trends are notable from the data in Table 2. First,
there is duplication of sequences in the—ostensibly random—
unselected library (R0).We believe that this phenomenonmay
result from a combination of errors occurring during synthesis
and sequencing. We have observed a strong bias for thymine
in ostensibly random libraries (data not shown), suggesting
synthesis bias. In addition, the majority of sequence duplica-
tion appears to result from contamination by the Illumina se-
quence adaptor. Second, the percent duplicated sequences in-
creases during the selection process, from around 10 % in the
unselected library DNA to around 40% after the fifth round of
selection. We interpret these data to mean that although the
unselected library is not composed of a random population of
unique DNA sequences—as is often assumed in SELEX—the
selection process nonetheless substantially modifies the DNA
pool. DNA collected from two rounds of negative selection
were also sequenced and served as a negative control in the
bioinformatics analysis. Certain sequences that were abundant
in the unselected oligo library persisted through multiple
rounds of selection. These sequences were abundant in both
positive and negative sequence pools, indicating that they are
parasitic, rather than truly selected. Sequences with high fold
Fig. 1 a Gel image showing the
effect of increasing the number of
PCR cycles. b Overlaid capillary
electropherograms showing the
effect of increasing cycle number
on PCR product. The traces have
been vertically offset for clarity
Table 2 Characteristics of data
resulting from Illumina
sequencing
SELEX round DNA sequenced Number of reads Sequence duplication
R0 Free 6.7×106 11.8 %
R1 Bound 3.8×106 13.0 %
R2+ Bound 2.7×106 14.0 %
R2− Bound 8.4×106 12.4 %
R3+ Bound 6.4×106 14.0 %
R3− Bound 5.3×106 20.0 %
R3− Free 6.2×106 14.0 %
R4 Bound 8.0×106 24.1 %
R5 Bound 10.1×106 37.7 %
SELEX round numbers are as described in Table 1. The unselected library is designated BR0^
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enrichment and cluster abundance were generally not found in
negative selection pools; therefore, we were able, through bio-
informatics analysis, to filter out these parasitic sequences in
silico. MPBind was used to assess possible binding potentials.
It was trained using all five rounds of positive selection and
used to calculate Z-scores for several highly enriched potential
aptamers.
Four promising aptamer sequences were chosen for testing.
We chose sequences that were enriched during the selection
process and were representative of large clusters. A control
sequence was also identified that showed little change in
abundance between the unselected pool and the selection
rounds. Table 3 shows the sequences that were selected for
in vitro characterization. Sequence A1 was the most enriched
sequence in R5, and it scores moderately well in sequence-
based clustering. It does not appear in any of the negative
selection rounds, nor does it have any homologs in the library
(defined as having a greater than 85 % sequence identity with
a sequence at ≥5 counts in the unselected library). In addition,
it scores well inMPBind (Z-score=10.75). Sequence A3 is the
third most enriched sequence in R5. Although slightly less
enriched than A1, it belongs to the largest sequence cluster.
It shares sequence homology with an overrepresented library
sequence, but achieving this alignment requires numerous
indels and mismatches that are not likely to have resulted from
PCR or sequencing error alone. Possibly due to this homolo-
gy, however, this sequence fairs poorly under MPBind with a
Z-score of −7.06. Sequence B10 is the second most enriched
sequence by R4. It appears in the largest sequence-based clus-
ter in that round, with no library homologs or counts in the
negative selection; it has a Z-score of −2.08. Unlike the other
aptamer sequences tested, B10 is 26 bases long; our bioinfor-
matics analysis was designed to include all sequences of
length 25±2. This 26mer sequence is possibly an artifact of
PCR or synthesis error, but we chose to study it because of its
high degree of enrichment. D3 is the sequence most enriched
in R2; it does not appear in the negative selection rounds, and
it has a moderately positive Z-score (1.6). Finally, L1 was
chosen as a negative control. It was the most abundant se-
quence in the unselected library and subsequent rounds, en-
abling us to test the hypothesis that a sequence that is initially
abundant may still bind to the protein target. However, the
sequence of L1 overlaps significantly with the Illumina index
adapter, suggesting that it might be a contamination intro-
duced post-SELEX.
Two orthogonal techniques—fluorescence anisotropy and
affinity probe capillary electrophoresis—were used to charac-
terize the binding of each aptamer candidate for the positive
Fig. 2 A flow chart showing the
steps involved in analyzing high-
throughput sequencing data col-
lected after a SELEX experiment
Table 3 HE4 aptamer candidates
chosen for in vitro analysis ID Round Rank Enrichment Sequence Z-
score
Cluster size
A1 5 1 26 TTATCGTACGACAGTCATCCTACAC 10.75 14
A3 5 3 22 CACAGTGCGTCACATTTAGGGCATT −7.06 46
B10 4 10 14 CAGTGCGTGCTTATTGGCGTAGCGTC −2.08 18
D3 2 3 12 ATGGTCGCAAGAACTGAGAATTTAC 1.6 10
L1 0 1 1 CCGTCTTCTGCTTGAAAAAAAAAAA −15.9 n/a
n/a not available
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selection protein target (HE4-GST). Figure 3 shows a repre-
sentative binding isotherm, for the aptamer A3, collected with
affinity probe CE, with increasing concentrations of HE-GST.
On the y-axis is plotted the height of the free DNA peak in the
absence of protein relative to the DNA peak in the presence of
protein. The data are reasonably well fit by the full form of the
binding isotherm equation. Table 4 summarizes the dissocia-
tion constant (Kd) values for the interaction of the five aptamer
candidates with HE4-GST. All four aptamers selected on the
basis of enrichment during selection displayed some affinity
for HE4-GST by one or both methods. The sequence D3 cho-
sen from the earliest selection round (R2) displayed the lowest
affinity in the anisotropy assay, and no detectable interaction
by affinity probe capillary electrophoresis (APCE), suggesting
that two selection rounds would not have been sufficient to
select a high-affinity aptamer for this particular target. The
negative control aptamer, L1, displays discrepant affinity
binding, with essentially no binding displayed in the fluores-
cence anisotropy assay and moderate affinity displayed in the
APCE assay. We are currently investigating the cause of this
discrepant binding behavior. In a previous study using CE-
SELEX and high-throughput sequencing to identify aptamers
for rhVEGF165, affinity CE and fluorescence anisotropy were
used to determine Kd values [23], yielding estimates ofKd that
differed by up to a factor of 7.3 between the two methods.
With the exception of the behavior of L1, our two affinity
characterization methods agree to an extent comparable to that
seen by other investigators in this area. We also tested the
affinity of all five sequences for binding to GST by APCE.
All five aptamers tested displayed no affinity for GST, with no
positive trend in ratioed peak heights over a concentration
range of GST from 0 to 250 nM (data not shown). The nega-
tive rounds of selection—in which aptamer candidates
displaying affinity for the free GST affinity tag were purged
from the DNA pool—seem to have been successful, as indi-
cated by these results.
In conclusion, we have demonstrated the proof of concept
for using capillary-based aptamer selection, high-throughput
sequencing, and a freely available bioinformatics pipeline to
select DNA aptamers with affinity for ovarian cancer bio-
marker HE4. The validity of this combination has also been
demonstrated by another very recent publication in this jour-
nal [31]. Our current efforts focus on improving the PCR
process to reduce the formation of by-products using emulsion
PCR [32] and using a six-histidine-modified HE4 as the target
protein in place of the more sterically hindered HE4-GST,
with the goal of selecting higher affinity aptamers than those
reported here. Aptamers with high binding affinity, reflected
by low nanomolar Kd values, are sought for use in bioassays
and in eventual clinical application. Inclusion of divalent cat-
ions in the selection buffer is also hypothesized to enable
greater diversity of secondary structure and therefore greater
binding affinity; selection in such a buffer is also in progress.
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